Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours

NCT00692354 | Completed Phase 1 DMC

• 1 other identifier: CHR-2797-001
• Study Type: interventional
• Target: 41
• Locations: 0 countries
• Sites: N/A

Brief Summary

The primary objective of this study was to determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered orally, once daily, to patients with advanced solid tumours. The secondary objectives of this study were:

• To determine pharmacokinetic parameters for CHR-2797 when administered orally at increasing dose levels;
• To investigate the pharmacodynamic effects of CHR-2797 in blood mononuclear cells and, when possible, tumour cells; - To enable a preliminary assessment of anti-tumour activity of CHR-2797.

Conditions

Advanced Solid Tumors

Keywords

Advanced; Solid; Tumour; Tumor; Oral

Outcome Measures

Primary Outcomes (1)

• To determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered orally, once daily, to patients with advanced solid tumours.

  3 years

Secondary Outcomes (3)

• To determine the PK parameters for oral CHR-2797 at increasing dose levels;

  3 years

• To investigate the PD effects of CHR-2797 in blood and tumour cells

  3 years

• To enable a preliminary assessment of anti-tumour activity of CHR-2797

  3 years

Interventions

CHR-2797 (tosedostat) DRUG

Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed, informed consent
• Histological or cytologically confirmed malignant solid tumour refractory to standard therapy or for which no standard therapy exists
• Evaluable disease
• Recovered from the acute adverse effects of prior therapies (excluding alopecia and grade 1 neuropathy)
• Adequate bone marrow, hepatic and renal function including the following:
• Hb ≥ 9.0 g/dl, absolute neutrophil count ≥ 1.5 x 109/L, platelets ≥ 100x109/L
• Total bilirubin ≤ 1.5 x upper normal limit
• AST and ALT ≤ 2.5 x upper normal limit (or ≤ 5 x UNL in the presence of liver metastases)
• Creatinine ≤1.5 x upper normal limit
• Age \< 18 years
• Performance status (PS) \< 2 (ECOG scale)
• Estimated life expectancy greater than 3 months
• Female patients with reproductive potential had to have a negative serum pregnancy test within 7 days of treatment. Both women and men had to agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuation of treatment. Acceptable methods of contraception included IUD, oral contraceptive, sub-dermal implant and double barrier (condom with a contraceptive sponge or contraceptive pessary)

You may not qualify if:

• Anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the 4 weeks prior to study entry (or a longer period depending on the defined characteristics of the agents used e.g. 6 weeks for mitomycin or nitrosourea). In patients with progressive disease (PD), continuation of LHRH agonists for prostate cancer, bisphosphonates for bone disease and corticosteroids was permitted provided the dose was stable before and during the study
• Co-existing active infection or serious concurrent illness
• Significant cardiovascular disease as defined by
• History of congestive heart failure requiring therapy
• History of unstable angina pectoris or myocardial infarction up to 6 months prior to study entry
• Presence of severe valvular heart disease
• Presence of a ventricular arrhythmia requiring treatment
• Any co-existing medical condition that in the Investigator's judgement substantially increased the risk associated with the patient's participation in the study
• Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies
• Gastrointestinal disorders that might have interfered with absorption of the study drug
• Persistent grade 2 or greater toxicities from any cause
• Patients with known brain tumours or metastases should have been excluded from this clinical study because of their poor prognosis and because they often develop progressive neurologic dysfunction that would have confounded the evaluation of neurologic and other AEs
• Pregnant or breast-feeding women

Sponsors & Collaborators

• Chroma Therapeutics: lead
• Institute of Cancer Research, United Kingdom: collaborator

MeSH Terms

Conditions

Neoplasms

Interventions

tosedostat

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: June 4, 2008
• First Posted: June 6, 2008
• Study Start: October 1, 2004
• Primary Completion: November 1, 2007
• Study Completion: March 1, 2008
• Last Updated: August 6, 2010

Record last verified: 2008-06